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ABSTRACT 
Background: The contents of the ship pharmacy, namely “medicine chest” and its compliance with the 
respective regulations concerning the type of drugs to be provided for merchant vessels involved in long 
distance voyages and without a doctor on board were analysed. The current existing disparity between 
regulations can make medical assistance more complicated, and more often of low quality, due to frequent 
off-label use of supplied drugs. This study may represent a starting point leading to a model high-quality 
medicine chest on board ships.
Materials and methods: A comparative analysis between the medicine chest requirements of 12 European 
countries and the CEE Directive 31 March 1992 n.92/29 was made. Prescriptions of the aforementioned 
Directive were compared with the WHO Model List of Essential Medicines (third Edition).
Results: The investigation showed a  lack of homogeneity of contents. It emerged that some medicine 
chests lack of several pharmaceutical categories required by the reference standards. The subsequent 
comparison of the European Directive with the WHO Model List of Essential Medicines has highlighted 
the absence of some therapeutic categories that in the ship environment can be of important to ensure 
adequate therapy in many situations.
Conclusions: There are disparities regarding regulations concerning the ship medicine chests. It is crucial to 
harmonize these and create a single medicine chest for all the ships without a doctor on board, undergoing 
periodic updates and revisions, based on epidemiological analysis that will ensure high-quality healthcare 
to seafarers around the world.
(Int Marit Health 2019; 70, 3: 143–150)
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INTRODUCTION
The set of medicines and other medical supplies on 
board ships is commonly referred to as the “medicine 
chest”. At the beginning of the eighteenth century and 
later in the nineteenth century, physicians who embarked 
carried with them a case containing some therapeutic aids 
of that time, to be used on board if necessary [1]. In the 
nineteenth century, with the increase of maritime traffic, 
various European States began to regulate health, safety 
and hygiene protocols on board ships. Some countries have 
compulsorily prescribed the presence of a “box (chest) of 
medications” on the ships [2]. An effort to harmonize Euro-
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pean regulations on health care on board ships was made 
at an international health conference held in Paris in 1851. 
The deliberations and declarations of this conference led to 
an agreement after which the signatory States undertook 
to evaluate the hygienic conditions of the vessels, food 
supplies, the health condition of crews and the presence 
of a “chest of medicinal products”, and in attachment the 
instructions for their use [3]. 
A  solution to keep the medicine chest updated and 
equipped according to the progress of pharmacotherapy 
is a  frequent review of international agreements to pro-
vide a well-stocked pharmacy on board ships. The lack of 
standardization of the ship’s medicine chest at the global 
level and the diversity in terms of medicines and medical 
equipment on board of different flagships make not easy 
the delivery of enough quality medical assistance on board 
of seagoing vessels. This is true primarily in case of medi-
cal advice provided by international Telemedical Maritime 
Assistance Services (TMAS).
The first global attempt to address this problem was ini-
tiated by World Health Organization (WHO) which published 
the first edition of the International Medical Guide for Ships 
in 1967. In this document, the WHO, along with a detailed 
appendix, recommended a minimum provision of medicinal 
products as standards that had to be maintained by all the 
ships in international waters [4]. The lack of consensus on 
standardized medicine chest on board ships still requires 
an international collaboration. WHO would represent the 
best-suited supranational organization to promote efforts 
of unifying the contents of on-board medicine chests. This 
problem is further complicated due to the diversity of laws 
and regulations that govern the distribution and use of 
medicinal products in different countries. At first, the min-
imum provision of medicines that each ship must have 
available on board was shown in two publications. They were 
namely: a) the International Medical Guide for Ships and b) 
the Medical First Aid Guide for Use in Accidents Involving 
Dangerous Goods [5]. On the other hand, many countries 
have regulated, for their fleet, the types and amounts of 
drugs which must be available on board. 
The European Union in the Directive (92/29/EEC) of 
the Council of 31 March 1992 on the minimum safety 
and health requirements for improved medical treatment 
on board ships, has issued a series of recommendations 
contained in the various annexes. The Annex II, which deals 
with the allocation of drugs on board ship is divided into 
nine large categories of medicines for the treatment of 
various diseases. For each therapeutic category, various 
drugs have been recommended [6]. The directive ensures 
that each ship carries drugs belonging to each therapeutic 
group, depending on the characteristics of the vessel. It 
also represents a general guideline for member states of 
the European Union. European countries having access to 
international waters must adapt their legislation in compli-
ance with this directive. 
The work of harmonization would be useful to reduce 
the differences in the possibility of delivering high-quality 
medical care to seafarers. Standardized protocols would get 
numerous benefits in the unified management of resources, 
in the preparation of uniform guidelines and treatment pro-
tocols and optimization of service on all ships. These efforts 
would bring economic benefits such as monitoring of costs 
and consumption of drugs, and especially a minor bureau-
cratic commitment for port authority which must check and 
inspect the drugs on board. The final result would be the 
implementation of a standardized management of onboard 
pharmacy allowing administering a drug to the patient from 
the symptoms until pre-hospitalization. 
Guidelines on the contents of the medicine chest could 
represent a relevant point to improve health conditions on 
board ships. In this analysis, we have compared the con-
tents of medicine chests, in terms of drugs, recommended 
by the legislation of the European States, for each therapeu-
tic class, referring to Annex II of the Directive (92/29/EEC), 
which is divided into nine major categories of medicinal 
products for the treatment of various pathologies [7]. The 
presence or absence of essential medicines indicated by 
WHO [8] in the different medicine chests was also analysed.
MATERIALS AND METHODS
In the “Annex II of the Directive (92/29/EEC)” published 
by the European Commission in March 1992 are reported 
the 9 major categories of medicinal products required to 
be on board for the treatment of various pathologies. This 
work has compared the contents of the “medicine chests” 
of some European reference maritime countries: France, 
Germany, Italy, Malta, Spain, United Kingdom, Denmark, 
Finland, Greece, Netherlands, Cyprus, and Portugal. 
The active principles included in the various medicine 
chests were classified into the nine major categories ac-
cording to the classification of the Annex II of the Directive 
(92/29/EEC) [7].
CYPRUS (CY), Section A. This section, published in 2010, 
lists medicines and medical aids required by Cyprus legisla-
tion for sea-going or sea-fishing vessels, with no limitation 
on the length of voyage [9].
DENMARK (DK), Section A. This section, published in 
2007, lists medicines and medical aids required by Danish 
legislation refers to the minimum provision of the medicine 
chest for ships with permission for worldwide voyages [10].
FINLAND (FI), Section A. This section, published in 2015, 
lists medicines and medical aids required by Finnish regula-
tions for sea-going or sea-fishing vessels, with no limitation 
on the length of voyage [11].
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FRANCE (FR), Section A. This section, published in 1996, 
lists medicines and medical aids required by French regu-
lations for vessels that do not carry passengers and are 
more than 24 hours away from the port of departure or 
8 hours or 100 miles from a nearby port which is equipped 
with a proper first aid [12].
GERMANY (DE), Section A2. This section, published in 
2006, lists medicines and medical aids required by German 
regulations for ships for merchant traffic and to international 
navigation short and long with 20 persons or more [13].
GREECE (GR), Section AII. This section, published in 
1995, lists the medicines and medical aids required by 
Greek regulations for vessels that do not carry passengers 
and with no limitation on the length of voyage [14].
ITALY (IT), Section C. This section, published in 2015, 
lists medicines and medical aids prescribed for domestic 
vessels and merchant ships for short and long international 
navigation [15].
MALTA (ML), Section A. This section, published in 2013, 
lists medicines and medical aids required by Maltese regu-
lations of the minimum provision for ships (including fishing 
vessels) with no limitation on length or voyages [16].
NETHERLANDS (NL), Section A. This section, published in 
2006, lists medicines and medical aids required by Dutch reg-
ulations refers to the limitation on the length of voyage [17].
PORTUGAL (PT), Section A. This section, published in 
1997, lists medicines and medical aids required by Portu-
guese regulations for sea-going or sea-fishing vessels, with 
no limitation on the length of voyage [18].
SPAIN (SP), Section A. This section, published in 1995, 
lists medicines and medical aids required by the Spanish 
regulations for vessels engaged in ocean voyages and with-
out a doctor on board [19].
UNITED KINGDOM (UK), Section A. This section pub-
lished in 2003, lists medicines and medical aids required 
by UK regulations for merchant ships or fishing boats nav-
igating international waters without travel time restriction 
and without a doctor on board [20].
As a second step, the list of medicines published in the 
above Annex II and those of the different countries consid-
ered were compared with the WHO Model List of Essential 
Medicines [8].
RESULTS
The results of the comparative analysis of the contents 
of medicinal products for systemic use recommended by 
the European Directive 92/29/EEC and of the 12 European 
countries examined are summarized in Tables 1 (Cardio-
vascular system, Gastro-intestinal system, Analgesics and 
antispasmodics, Nervous system) and 2 (Anti-allergic and an-
ti-anaphylactic, Respiratory system, Anti-infection, Compounds 
promoting rehydration, caloric intake and plasma expansion). 
As shown in Table 1, all 5 classes of cardiovascular 
drugs indicated by the European Directive are present. For 
the medicines acting on the gastrointestinal system, Hista-
mine H2 receptor anti-ulcer antagonists are missing from 
the German, Danish, Finland, French and Dutch medicine 
chests, whereas the other 6 classes of gastro-intestinal 
compounds are present. It should be mentioned that in the 
above five on-board medicine chests, proton pump inhibi-
tor drugs, such as omeprazole, replace the H2-antagonist 
antiulcer. Even if these are drugs with a different mecha-
nism of action and pharmacokinetics, the therapeutic use 
is the same, and they can be therefore considered to be 
interchangeable.
Analgesic and antispasmodics are present in the medi-
cine chests of all countries, except for spasmolytics missing 
in the Danish, Finnish and Dutch chests. All recommended 
nervous system compounds are present in the medicine 
chests of the 12 countries considered. 
Analysis of Table 2 shows that all classes of Anti-allergic 
and anti-anaphylactic, Respiratory system, Anti-infection, 
Compounds promoting rehydration, caloric intake and plas-
ma expansion, recommended by the European Directive 
are included in the medicine chests of the 12 countries 
examined, except for the anti-bacterial sulphonamide, which 
is missing in the Finnish and French medicine chests.
Table 3 summarizes medicines for external use indicat-
ed in the European Directive included in the medicine chests 
of the 12 countries examined. In general, there is a good 
correspondence between the European recommendations 
and the contents of single country medicine chests. The 
only exceptions are for skin medicines, antibiotic ointments/ 
/creams missing in the Danish medicine chest, the antibiotic 
and anti-inflammatory drops missing in the eye medicines 
required by Dutch regulations, the antibiotic solutions list-
ed in the ear medicines section absent in the Danish and 
Germany medicine chest. The antibiotic or antiseptic mouth-
washes of the section Medicines for oral or throat infections 
missing in the Finnish medicine chest.
Data of the analysis of the presence in the “Annex II of 
the Directive (92/29/EEC)” the so-called Model List Essen-
tial Medicine proposed by the WHO, serving as a guide to 
the development of the national and institutional essential 
medicine lists [8] are summarized in Table 4. As shown, 
the main inconsistencies are in the absence of antimalar-
ial, antileprosy, antituberculosis and anthelminthics and 
antiprotozoals medicines for the Anti-infective medicines 
class. For the class of Medicines affecting blood, the lack 
of antianaemia medicines, blood coagulation factors, plas-
ma-derived medicines, and plasma substitutes is notice-
able. In the section Hormones, other endocrine medicines 
and contraceptives, the lack of insulins and other medicines 
used for diabetes and thyroid hormones and antithyroid 
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Table 1. Cardiovascular system, Gastro-intestinal system, Analgesics and antispasmodics, Nervous system medicinal products listed 
in the Annex II of the Directive (92/29/EEC) included (P) or not included (A) in the medicine chests of the 12 European countries 
examined
Drugs CY DE DK FI FR GR IT ML NL PT SP UK WHO
Cardiovascular                      
Cardio-circulatory analeptics — sympathomimetics P P P P P P P P P P P P P
Anti-angina preparations P P P P P P P P P P P P P
Diuretics P P P P P P P P P P P P P
Anti-haemorrhagics including uterotonics  
if there are women on board
P P P P P P P P P P P P P
Anti-hypertensive P P P P P P P P P P P P P
Gastro-intestinal system
Medicines for gastric and duodenal disorders
— Histamine H2 receptor anti-ulcer antagonists P A A A A P P P A P P P P
— Anti-acid mucous dressings P P P P P P P P P P P P P
Anti-emetics P P P P P P P P P P P P P
Lubricant laxatives P P P P P P P P P P P P P
Anti-diarrhoeals P P P P P P P P P P P P P
Intestinal antiseptics P P P P P P P P P P P P P
Haemorrhoid preparations P P P P P P P P P P P P P
Analgesics and anti-spasmodics
Analgesics, anti-pyretics and anti-inflammatory 
preparations
P P P P P P P P P P P P P
Powerful analgesics P P P P P P P P P P P P P
Spasmolytics P P A A P P P P A P P P P
Nervous system
Anxiolytics P P P P P P P P P P P P P
Neuroleptics P P P P P P P P P P P P P
Seasickness remedies P P P P P P P P P P P P P
Anti-epileptics P P P P P P P P P P P P P
CY — Cyprus, DE — Germany, DK — Denmark, FI — Finland, FR — France, GR — Greece, IT — Italy, ML — Malta, NL — Netherlands, PT — Portugal, SP — Spain, UK — United 
Kingdom; WHO — World Health Organization
medicines was observed. Medicines used for depressive 
disorders are missing in the section Medicines used in 
mood disorders.
The results of a further analysis of the presence or 
absence of medicinal products included in the WHO Mod-
el List of Essential Medicines in the different medicine 
chest of the 12 European countries examined are sum-
marized in Table 5. As shown, several inconsistencies 
are noticeable.
DISCUSSION
In addition to the legal and logistic issues pertaining to 
the procurement of specific drugs in different countries of 
the world, this lack of standardization can be an additional 
obstacle to effective treatment of diseases and accidents 
on board ships. A fundamental requirement to guarantee 
high-quality care is the availability of drugs that increase 
the possibility of an appropriate therapeutic choice for the 
treatment of various diseases more often occurring on board 
ships. Ideally, the medicine chest, taking into account this 
particularly sensitive category of workers, has to be validat-
ed and be uniform for all the ships worldwide, independently 
from the flags that they are registered under. Life-saving 
medicines, that are required to treat certain serious medical 
conditions emergencies, should have priority and serve as 
the starting point for the desirable standardization of regu-
lation of this matter, both in terms of types and quantities 
of therapeutic principles to carry on ships. 
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Table 2. Anti-allergic and anti-anaphylactic, Respiratory system, Anti-infection, Compounds promoting rehydration medicinal products listed 
in the Annex II of the Directive (92/29/EEC) included (P) or not included (A) in the medicine chests of the 12 European countries examined
Drugs CY DE DK FI FR GR IT ML NL PT SP UK WHO
Anti-allergics and anti-anaphylactic
H1 Anti-histaminics P P P P P P P P P P P P P
Injectable glucocorticoids P P P P P P P P P P P P P
Respiratory system
Bronchospasm preparations P P P P P P P P P P P P P
Anti-tussives P P P P P P P P P P P P P
Medicines used for colds and sinusitis P P P P P P P P P P P P P
Anti-infection
Antibiotics (at least two families) P P P P P P P P P P P P P
Anti-bacterial sulphonamide P P P A A P P P P P P P P
Urinary antiseptics P P P P P P P P P P P P P
Anti-parasitics P P P P P P P P P P P P P
Intestinal anti-infectives P P P P P P P P P P P P P
Anti-tetanus vaccines and immunoglobulins P P P P P P P P P P P P P
Compounds promoting rehydration, caloric  
intake, and plasma expansion
P P P P P P P P P P P P P
Abbreviations are the same as in the legend to Table 1
Table 3. Medicines for external use listed in the Annex II of the Directive (92/29/EEC) included (P) or not included (A) in the medicine 
chests of the 12 European countries examined
Drugs CY DE DK FI FR GR IT ML NL PT SP UK WHO
Medicines for external use
Skin medicines
— Antiseptic solutions P P P P P P P P P P P P P
— Antibiotic ointments P P A P P P P P P P P P P
— Anti-inflammatory and analgesic ointments P P P P P P P P P P P P P
— Anti-mycotic skin creams P P P P P P P P P P P P P
— Burn preparations P P P P P P P P P P P P P
Eye medicines
— Antibiotic drops P P P P P P P P P P P P P
— Antibiotic and anti-inflammatory drops P P P P P P P P A P P P P
— Anaesthetic drops P P P P P P P P P P P P P
— Hypotonic myotic drops P P P P P P P P P P P P P
Ear medicines
— Antibiotic solutions P A A P P P P P P P P P P
— Anaesthetic and anti-inflammatory solutions P P P P P P P P P P P P P
Medicines for oral and throat infections
— Antibiotic or antiseptic mouthwashes P P P A P P P P P P P P P
Local anesthetics
— Local anaesthetics using freezing P P P P P P P P P P P P P
— Local anaesthetics given by subcutaneous injection P P P P P P P P P P P P P
— Dental anaesthetic and antiseptic mixtures P P P P P P P P P P P P P
Abbreviations are the same as in the legend to Table 1
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Table 4. Comparison between the WHO Essential Model List and those listed in the “Annex II of the Directive (92/29/EEC)”
WHO Model List of Essential Medicines, 2017 Included in the European  
Directive 92/29/EEC
MEDICINES FOR PAIN AND PALLIATIVE CARE Present
ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS Present
ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS Present
ANTICONVULSANTS/ANTIEPILEPTICS Present
ANTI-INFECTIVE MEDICINES  
Antibiotics (at least two families) Present
Anti-bacterial sulphonamide Present
Urinary antiseptics Present
Anti-parasitics Present
Anti-malarial* Absent
Intestinal anti-infectives Present
Anti-tetanus vaccines and immunoglobulins Present
Antileprosy medicines* Absent
Antituberculosis medicines* Absent
Anthelmintics and Antiprotozoals* Absent
ANTIMIGRAINE MEDICINES Present
MEDICINES AFFECTING THE BLOOD  
Antianaemia medicines* Absent
Medicines affecting coagulation Present
Blood coagulation factors* Absent
Plasma-derived medicines and Plasma substitutes* Absent
CARDIOVASCULAR MEDICINES Present
DERMATOLOGICAL MEDICINES (topical) Present
DIAGNOSTIC AGENTS Present
DISINFECTANTS AND ANTISEPTICS Present
DIURETICS Present
GASTROINTESTINAL MEDICINES Present
HORMONES, OTHER ENDOCRINE MEDICINES, AND CONTRACEPTIVES  
Adrenal hormones and synthetic substitutes Present
Insulins and other medicines used for diabetes* Absent
Thyroid hormones and antithyroid medicines* Absent
MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE INHIBITORS Present
OPHTHALMOLOGICAL PREPARATIONS Present
MEDICINES USED IN MOOD DISORDERS  
Anxiolytics Present
Neuroleptics Present
Medicines used in depressive disorders* Absent
*Categories of medicinal products not included in the “Annex II of The Directive (92/29/EEC)”
Among the most relevant Essential Medicines not includ-
ed in the medicine chests, there is a major shortage for the 
class “Medicines Affecting Coagulation” in terms of content 
of drugs interfering with coagulation mechanisms. Seafarers 
are particularly exposed to the risk of serious accidents [21], 
which can result in bleeding. Circulatory system diseases 
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Table 5. Analysis of the availability of pharmacological specialties reported in the WHO Model List of Essential Medicines, not  
included in the European guidelines (Annex II European Directive 92/29/EEC), as shown in Table 4
Drugs CY DE DK FI FR GR IT ML NL PT SP UK
Anti-malarial A P P P P P P P P A A A
Antileprosy medicines A A A A A P A P A A A A
Antituberculosis medicines A A A A A A A A A A A A
Anthelminthics and Antiprotozoals P P P A P P P P A P P P
Antianaemia medicines A P A A A A A A A A A A
Blood coagulation factors P P A P P P A P P A P A
Plasma-derived medicines and Plasma substitutes A A P A A P P P P P P P
Insulins and other medicines used for diabetes A A A P P A P A A A A P
Thyroid hormones and antithyroid medicines A A A A A A A A A A A A
Medicines used in depressive disorders A A A A A A A A A A A A
Abbreviations are the same as in the legend to Table 1
are the most frequent death causes, followed by external 
causes such as accidents and violence [22]. In view of this, 
availability of certain life-saving drugs is desirable for giving 
as much as possible proper health care and preventing 
fatalities. Another shortage is represented by antiprotozoal, 
antimalarial, anthelmintic, scabicides and pediculicides. 
The “Annex II of the Directive (92/29/EEC)” as well as other 
European Medicine chests lack of many products of this 
class (Table 2). This may be problematic as infectious and 
parasitic diseases occupy the 3rd place among the causes 
of death on board ships [22]. Moreover, “Medicines used 
in mood disorders” such as subclass of antidepressants, 
included in the WHO Model List of Essential Medicines, are 
missing from the “Annex II of the Directive (92/29/EEC)” 
(Table 2). This is another important lack, because seafarers 
may experience psycho-emotional problems and increased 
fatigue [23]. Another class of drugs absent from European 
Medicine chests are antidiabetic drugs such as insulin, met-
formin, glucagon and other specialties, provided by the WHO 
Model List of Essential Medicines, present only in Finland, 
France, Italy and United Kingdom medical chests. The lack 
of certain types of drugs may force doctors to make different 
prescriptions from those, which they would have made in the 
case of availability of more specific therapeutic agents [24]. 
One consequence of this shortage may be a great off-label 
use of medications. Off-label prescriptions is allowed and 
from time to time is useful, but if exaggerated can lead to 
non-negligible problems [25–26]. 
The comparative analysis between the ”Annex II of the 
Directive (92/29/EEC)” and the WHO Essential Model List 
confirms the presence on board ships of active substances, 
which are considered to be lifesaving such as penicillin, 
hydrocortisone, adrenaline, furosemide, anti-tetanus im-
munoglobulin. These are all included in the ship medicine 
chest, although a greater possibility of choice in terms of 
formulation for these active principles would be desirable. In 
general there is a good correspondence between essential 
medicines recommended by the WHO Model List, those 
required by the European Directive — Annex II 92/29CEE 
(see Table 5) and the contents of the 12 medicine chests 
studied. However, the lack of antimalarial medications in 
some flag states regulations remains an issue, taking into 
account that merchant ship may sail in areas identified as 
epidemiological outbreaks of this parasitosis. 
Seafarers should benefit of both preventive and thera-
peutic health care approaches. This requires the ability to 
identify and assess risks in workplaces and the systematic 
recording of environmental stress and their pathological, 
pathophysiological and psychological effects. To ensure an 
adequate level of medical care, the appropriate stocks of 
drugs and medical equipment is necessary. From this avail-
ability depends on much of the opportunity to provide quality 
medical assistance to seafarers. An adequate provision of 
drugs, together with enough quality telemedical assistance, 
may guarantee health/life protection of seafarers at sea [27]. 
CONCLUSIONS
The results of this work suggest the need of a revision 
of national and international regulations, aimed at the de-
velopment of a universal ship’s medicine chest, based on 
dedicated pharmacoepidemiologic studies. Another issue 
that should be considered is the periodic and frequent 
update of these lists. In this way, thanks to technological 
evolution we will be able to shorten distances and take ad-
vantage of a high quality medical assistance at sea. The best 
solution to the problem of medicine chest standardization 
is to homogenize them to ensure that any ship sailing in 
international waters carries well-equipped and standardized 
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medicine chest. This will be helpful for seafarers and those 
from ashore are treating them.
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